ALISHA MERCHANT Alisha is passionate professional with a strong educational background in the healthcare field
GLP-1 Medications Are Different: Pharmaceutical GLP-1 medications are synthetic versions engineered to: Last much longer in your body (days instead of minutes) Resist breakdown by enzymes Maintain therapeutic levels continuously Produce stronger, sustained effects than natural GLP-1 Think of it this way: Natural GLP-1: Brief Im full signal during meals GLP-1 medications: Continuous youre satisfied, dont overeat signal all week Types of GLP-1 Medications: Pure GLP-1 Receptor Agonists: These activate only GLP-1 receptors: Semaglutide: Brand names: Wegovy (weight loss), Ozempic (diabetes) Dosing: Once weekly injection Average weight loss: 10-15% of body weight FDA approved: 2017 (Ozempic), 2021 (Wegovy) Liraglutide: Brand name: Saxenda (weight loss), Victoza (diabetes) Dosing: Daily injection Average weight loss: 5-8% of body weight Older, less effective than semaglutide Dulaglutide: Brand name: Trulicity Dosing: Once weekly injection Primarily for diabetes, not typically used for weight loss Dual GIP/GLP-1 Receptor Agonist: Tirzepatide: Brand names: Zepbound (weight loss), Mounjaro (diabetes) Dosing: Once weekly injection Average weight loss: 15-22% of body weight FDA approved: 2022 (Mounjaro), 2023 (Zepbound) Most effective weight loss medication available What Makes Tirzepatide Different: Tirzepatide activates two hormone receptors instead of one: GLP-1 Effects (same as semaglutide): Appetite suppression Slowed stomach emptying Increased insulin secretion Reduced glucagon production Plus GIP Effects: Enhanced insulin response Improved insulin sensitivity Effects on fat metabolism Additional appetite suppression Result: 5-7% more weight loss than semaglutide alone, making tirzepatide the most effective option
PMID 18949650
It is acknowledged that the stimulation of signal transducers and activators of transcription 3 (STAT3) is essential for the transformation into the M2 subtype, whereas the activation of STAT1 is a crucial determinant for the M1 subtype [85]
Ms Feszczur also suggests patients taper from GLP-1 agonists rather than immediate cessation
With Trulicity, patients may be able to lose some weight
